A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01726348 |
Recruitment Status
:
Withdrawn
(The company decided to cancel this study in conformity with PH FDA Circular 2013-004)
First Posted
: November 14, 2012
Last Update Posted
: December 2, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Human Immunodeficiency Virus-Type 1 | Drug: No intervention |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | A Post-Marketing Surveillance Study on the Safety and Effectiveness of Darunavir on Filipino Patients With Human Immunodeficiency Virus-Type I (HIV-1) Infection |
Study Start Date : | January 2014 |
Estimated Primary Completion Date : | December 2014 |
Estimated Study Completion Date : | December 2014 |

Group/Cohort | Intervention/treatment |
---|---|
Darunavir
Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
|
Drug: No intervention
This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
|
- Number of patients with incidence of adverse events [ Time Frame: Up to 24 weeks ]
- Number of patients with incidence of discontinuation of study medication due to adverse events [ Time Frame: Up to 24 weeks ]
- Mean decrease of viral load at the end of treatment from baseline [ Time Frame: Baseline, Week 12, and Week 24 ]
- Number of patients with viral load of 50 copies per ml at the end of treatment [ Time Frame: Baseline, Week 12, and Week 24 ]
- Number of patients with lack of effect [ Time Frame: Up to 24 weeks ]Any failure of expected pharmacologic action of the study medication

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients who are diagnosed with human immunodeficiency virus-type 1 (HIV-1), and who are eligible for darunavir (in combination with ritonavir) treatment. These may be either: treatment-naive adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions; or treatment-experienced adult patients with at least one darunavir resistance associated substitution
Exclusion Criteria:
- Known hypersensitivity to darunavir/ritonavir or to any of the components of the two agent preparations
- Pregnant or breastfeeding females
- Agrees to protocol-defined use of effective contraception
- Patients taking medication that are highly dependent on Cytochrome P450 3A4 for clearance and for which initial concentrations are associated with serious and/or life threatening events
- Patients with severe hepatic impairment
- History of allergy to sulfa containing drugs or molecules
- Patients currently receiving alfuzosin, dihydroergotamine, ergonovine, ergotamine, methylergonavine, cisapride, pimozide, midazolam, triazolam, St. John's Wort (Hypericum perforatum), lovastatin, simvastatin, rifampin and sildenafil

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01726348
Study Director: | Janssen Pharmaceutica Clinical Trial | Janssen Pharmaceutica |
Responsible Party: | Janssen Pharmaceutica |
ClinicalTrials.gov Identifier: | NCT01726348 History of Changes |
Other Study ID Numbers: |
CR014686 TMC114HIV4013 ( Other Identifier: Janssen Pharmaceutica ) PRE-PHL-MA1 ( Other Identifier: Janssen Pharmaceutica ) TMC-C-07-PH-007 ( Other Identifier: Janssen Pharmaceutica ) |
First Posted: | November 14, 2012 Key Record Dates |
Last Update Posted: | December 2, 2015 |
Last Verified: | November 2015 |
Keywords provided by Janssen Pharmaceutica:
Human Immunodeficiency Virus-Type 1 HIV-1 TMC114 |
Darunavir Ritonavir Filipino |
Additional relevant MeSH terms:
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Ritonavir |
Darunavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |